Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA

Mayr, Anton; Hochstein‐Mintzel, V.; Stickl, H

doi:10.1007/bf01641272

Cited by 217 publications

(132 citation statements)

References 17 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…m8rc (plaque-purified m8 to minimize contamination by revertants) and the revertant viruses (LPCs) were isolated from the m8 stock by three serial plaque purifications in RK13 cells. The modified VV Ankara (MVA) (26,27) and Western Reserve (WR) viruses were obtained from S. Morikawa (National Institute of Infectious Diseases, Tokyo). MVA was propagated and titrated in chicken embryo fibroblasts.…”

Section: Methodsmentioning

confidence: 99%

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

Kidokoro

Tashiro

Shida

2005

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

A highly attenuated LC16m8 (m8) smallpox vaccine has been licensed in Japan because of its extremely low neurovirulence profile, which is comparable to that of replication incompetent strains of vaccinia virus. From 1973 to 1975, m8 was administrated to >100,000 infants where it induced levels of immunity similar to that of the originating Lister strain, without any serious side effects. Recently, we observed that m8 reverts spontaneously to large plaque forming clones that possess virulence equivalent to that of LC16mO, a parental virus strain of m8. Here, we report that the B5R gene is responsible for the reversion, and that we could construct a more genetically stable virus by deleting B5R from m8. The protective immunogenicity of the vaccine candidate proved to be equivalent to that of the U.S.-licensed product Dryvax, and much superior to modified vaccinia Ankara in a mouse model. Furthermore, the vaccine strain never elicited any symptoms in severe combined immunodeficiency disease mice, even at a dose 1,000-fold greater than that used in the immune protection experiments, which is in contrast to the lethal pathogenicity induced by Dryvax inoculation of severe combined immunodeficiency disease mice. Our results suggest that this vaccine strain is a good candidate as a suitable smallpox vaccine and a vector virus, and that B5R is not essential for protective immunity against smallpox.B5R gene ͉ reversion ͉ Lister strain ͉ extracellular enveloped virion

show abstract

Section: Methodsmentioning

confidence: 99%

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

Kidokoro

Tashiro

Shida

2005

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…MVA is an attenuated smallpox vaccine that fails to replicate in most mammalian cells. 45 The fragment coding for RENTA was inserted into the thymidine kinase locus of the virus genome under the P7.5 early/ late promoter using plasmid pSC11, which codelivered a b-galactosidase gene facilitating the screening, titration and stability studies of the recombinant MVA.RENTA. 18 This marker enzyme is commonly expressed by human enteric bacteria and has been safely used in several clinical trials including healthy HIV-uninfected volunteers vaccinated with MVA.HIVA.…”

Section: Design Of the Renta Immunogenmentioning

confidence: 99%

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

Nkolola

et al. 2004

Gene Ther

View full text Add to dashboard Cite

For the development of human immunodeficiency virus type 1 (HIV-1) vaccines, traditional approaches inducing virus-neutralizing antibodies have so far failed. Thus the effort is now focused on elicitation of cellular immunity. We are currently testing in clinical trials in the United Kingdom and East Africa a T-cell vaccine consisting of HIV-1 clade A Gag-derived immunogen HIVA delivered in a prime-boost regimen by a DNA plasmid and modified vaccinia virus Ankara (MVA). Here, we describe engineering and preclinical development of a second immunogen RENTA, which will be used in combination with the present vaccine in a four-component DNA/HIVA-RENTA prime-MVA/HIVA-RENTA boost formulation. RENTA is a fusion protein derived from consensus HIV clade A sequences of Tat, reverse transcriptase, Nef and gp41. We inactivated the natural biological activities of the HIV components and confirmed immunogenicities of the pTHr.RENTA and MVA.RENTA vaccines in mice. Furthermore, we demonstrated in mice and rhesus monkeys broadening of HIVAelicited T-cell responses by a parallel induction of HIVA-and RENTA-specific responses recognizing multiple HIV epitopes.

show abstract

“…[29][30][31] Such risks are particularly acute in adjuvant cancer immunotherapy protocols, where patients may be in an immunocompromised state because of their disease or primary therapy. The use of replication-defective vaccinia viruses such as MVA 49 may go some way to addressing these problems, however, rFWPV may have particular advantages. The host range restriction may not be so complete for MVA as for FWPV.…”

Section: Figure 7 Human DC Infected With Fowlpox Virus Retain Viabilimentioning

confidence: 99%

Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity

et al. 2000

View full text Add to dashboard Cite

The identification of dendritic cells (DC) as the major antigen-presenting cell type of the immune system, combined with the development of procedures for their ex vivo culture, has opened possibilities for tumour immunotherapy based on the transfer of recombinant tumour antigens to DC. It is anticipated that the most effective type of response would be the stimulation of specific, MHC class I restricted cytotoxic T lymphocytes capable of recognising and destroying tumour cells. In order to make this approach possible, methods must be developed for the transfer of recombinant antigen to the DC in such a way that they will initiate an MHC class I restricted response. Here, we demonstrate that murine DC infected with a recombinant fowlpox virus (rFWPV) vector stimulate a powerful, MHC class I restricted response against a recombinant antigen. A rFWPV containing the OVA gene was constructed and used to infect the DC line

show abstract

Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA

Cited by 217 publications

References 17 publications

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity

Contact Info

Product

Resources

About